Use one of the following options to find your doctor at Cabrini
or
Malvern
Brighton

Looking for a physiotherapist or other professional? See Allied Health

Cancer Trials at Cabrini

The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.

 

Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.

Phase I

A Phase 1b/2 Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-cell Lymphoid Malignancies

Protocol Number - BGB-311_GA101_Study_001

Download more information >

A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Protocol Number - CPI-444-001

Download more information >

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications

Protocol Number - EMR 200647-001

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

Melanoma

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

Lung

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti−PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage IB−IIIA Non−Small Cell Lung Cancer

Protocol Number - GO29527

Download more information >

A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin in First Line Therapy in unresectable Pleural Mesothelioma

Protocol Number - CA209743

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

Haematological / Blood cancers

A Phase II, international, multicentre, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (oral Azacitidine) alone and in combination with Durvalumab (MEDI4736) in subjects with Myelodysplastic syndromes who fail to achieve an objective response to treatment with Azacitidine for injection or Decitabine

Protocol Number - CC-486-MDS-006

Download more information >

A Phase 1b/2 Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-cell Lymphoid Malignancies

Protocol Number - BGB-311_GA101_Study_001

Download more information >

A Phase 3, Multicentre, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine plus Best Supportive Care versus Placebo plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes

Protocol Number - AZA-MDS-003

Download more information >

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

Colorectal

Circulating Tumour DNA Analysis Informing Adjuvant Chemo in Stage II Colon Cancer (DYNAMIC)

Protocol Number - WEHI - ctDNA - 04

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

Genitourinary

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination with Patinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Protocol Number - WO30070

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Protocol Number - CO-338-052

Download more information >

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Protocol Number - CA209914

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

Breast Cancer

A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Protocol Number - CPI-444-001

Download more information >

A randomized, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of Olaparib versus placebo as adjuvant treatment in patients with germline BRACA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (Olympia)

Protocol Number - BIG 6-13, NASBP B-55

Download more information >

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus
Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) (KEYNOTE-522)

Protocol Number - 522-01

Download more information >

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Protocol Number - ONT-380-206

Download more information >

Gynaecological

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MPL0128 in Women with Advanced, Recurrent, or Persistent Endometrial Cancer

Protocol Number - C31004

Download more information >

A Phase II trial of DuRvalumab (Medi 4736) in Advanced Endometrial Cancer “PHAEDRA”

Protocol Number - CTC0144/ANZGOG1601

Download more information >

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Protocol Number - YO39523

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I-III Optimally Debulked Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC).

Protocol Number - WEHI-ctDNA-10

Download more information >

Gastrointestinal

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

Pancreatic

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Protocol Number - AM0010-301

Download more information >

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Protocol Number - CanStem111P

Download more information >

There are no results to your search.

The keyword you entered is too short. Please use at least three characters.